GlaxoSmithKline plc: PharmaVitae Profile

GlaxoSmithKline plc: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical sector

*Assess the threat posed by generic competition to GlaxoSmithKline's core prescription pharmaceutical business

*Analyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
GlaxoSmithKline: PharmaVitae forecasts at a glance 8
Strategic insight 9
Introduction 9
Analysis of sales performance 2002-08 9
Analysis of sales performance 2008-14 10
Outlook 14
SWOT analysis 16
Strengths 17
Weaknesses 18
Opportunities 18
Threats 20
TABLE OF CONTENTS 22
Table of figures 24
Chapter 3 Quarterly news update 25
Product developments 25
Deals and alliances 27
Product deals 27
Technology deals 32
M&A activity 33
Company announcements 33
Future product milestones 35
Chapter 4 Company introduction 38
Key findings 38
Background 39
M&A history 39
Glaxo and Wellcome 39
Glaxo Wellcome 39
Smith Kline and Beecham 39
SmithKline Beecham 40
Key historical drug launches by component GSK companies 41
M&A strategy 41
R&D overview 44
Chapter 5 Company sales 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2002-14 47
Product analysis 49
Product analysis, 2002-08 50
Product analysis, 2008-14 53
Therapy area analysis 56
Geographic analysis 59
Launch/core/expiry analysis 61
Explanation of launch/core/expiry analysis 61
Launch analysis, 2008-14 62
Core analysis, 2008-14 65
Expiry analysis, 2008-14 66
Launch/core/expiry configuration, 2008-14 68
Molecule type analysis 69
Externalization analysis 73
Chapter 6 Company financials 76
Key findings 76
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 77
Operating costs and profit analysis 78
Operating costs and profit analysis, 2002-08 79
Operating cost ratio and profit margin analysis, 2002-08 80
Operating cost ratio and profit margin analysis, 2008-14 81
Operating costs and profit analysis, 2008-14 82
Chapter 7 Key products and competitors 83
Overview 83
Respiratory 84
Seretide/Advair 84
Overview 84
Sales forecast 85
Beyond Advair 87
Overview 87
Sales forecast 88
Infectious diseases 89
Cervarix 89
Overview 89
Sales forecast 90
Valtrex 93
Overview 93
Sales forecast 94
Oncology 95
Tykerb/Tyverb 95
Overview 95
Sales forecast 96
Genitourinary 98
Duodart 98
Overview 98
Sales forecast 99
Central Nervous system 100
Almorexant 100
Overview 100
Sales forecast 101
Lamictal 102
Overview 102
Sales forecast 103
Imigran/Imitrex 105
Overview 105
Sales forecast 106
Endocrinology 108
Avandia 108
Overview 108
Sales forecast 109
Chapter 8 Appendix 112
R&D pipeline 112
Abbreviations 115
Exchange rates 116
About Datamonitor 117
About Datamonitor Healthcare 117
Datamonitor consulting 117
Disclaimer 119

LIST OF TABLES
Table 1: GlaxoSmithKline - PharmaVitae forecasts at a glance 8
Table 2: GlaxoSmithKline vaccine sales ($m), 2008-14 13
Table 3: GlaxoSmithKline key product developments, 2009 25
Table 4: GlaxoSmithKline product deals and alliances, 2009 27
Table 5: GlaxoSmithKline technology deals and alliances, 2009 32
Table 6: GlaxoSmithKline M&A activity, 2009 33
Table 7: GlaxoSmithKline company announcements, 2009 33
Table 8: GlaxoSmithKline future product milestones, 2009-11 35
Table 9: GlaxoSmithKline product portfolio overview ($m), 2002-08 50
Table 10: GlaxoSmithKline product portfolio overview ($m), 2008-14 53
Table 11: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2008-14 57
Table 12: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2008-14 60
Table 13: GlaxoSmithKline launch portfolio overview ($m), 2008-14 62
Table 14: GlaxoSmithKline core portfolio overview ($m), 2008-14 65
Table 15: GlaxoSmithKline expiry portfolio overview ($m), 2008-14 66
Table 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2008-14 70
Table 17: GlaxoSmithKline vaccine sales ($m), 2008-14 71
Table 18: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2008-14 74
Table 19: Total GlaxoSmithKline sales by business unit ($m), 2002-08 77
Table 20: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-08 79
Table 21: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2002-08 80
Table 22: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2008-14 81
Table 23: GlaxoSmithKline operating revenue/cost analysis ($m), 2008-14 82
Table 24: GlaxoSmithKline Key products overview 83
Table 25: Seretide/Advair: overview 84
Table 26: Seretide/Advair: sales forecast ($m), 2008-14 85
Table 27: Beyond Advair: overview 87
Table 28: Beyond Advair: sales forecast ($m), 2008-14 88
Table 29: Cervarix: overview 89
Table 30: Cervarix: sales forecast ($m), 2008-14 90
Table 31: Valtrex: overview 93
Table 32: Valtrex: sales forecast ($m), 2008-14 94
Table 33: Tykerb/Tyverb: overview 95
Table 34: Tykerb/Tyverb: sales forecast ($m), 2008-14 96
Table 35: Duodart: overview 98
Table 36: Duodart: sales forecast ($m), 2008-14 99
Table 37: Almorexant: overview 100
Table 38: Almorexant: sales forecast ($m), 2008-14 101
Table 39: Lamictal: overview 102
Table 40: Lamictal: sales forecast ($m), 2008-14 103
Table 41: Imigran/Imitrex: overview 105
Table 42: Imigran/Imitrex: sales forecast ($m), 2008-14 106
Table 43: Avandia: overview 108
Table 44: Avandia: sales forecast ($m), 2008-14 109
Table 45: GlaxoSmithKline's R&D pipeline (Phase I-registration) 112
Table 46: Exchange rates, 2009 116
LIST OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: GlaxoSmit6thKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: GlaxoSmithKline's financial performance ($m), 2002-14 7
Figure 4: GlaxoSmithKline launch/core/expiry configuration ($m), 2002-08 9
Figure 5: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 10
Figure 6: GlaxoSmithKline prescription pharmaceutical sales growth by molecule type ($m), 2008-14 12
Figure 7: GlaxoSmithKline SWOT analysis 16
Figure 8: M&A/divestment history 40
Figure 9: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 47
Figure 10: Key product sales ($m), 2002-14 49
Figure 11: GlaxoSmithKline key sales growth drivers and resistors ($m), 2002-08 52
Figure 12: GlaxoSmithKline key sales growth drivers and resistors ($m), 2008-14 55
Figure 13: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2002-14 56
Figure 14: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2002-14 59
Figure 15: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 68
Figure 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2002-14 69
Figure 17: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2002-14 73
Figure 18: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-14 78